FDA Advisory Panel Backs Six Peptides, Including BPC-157 and KPV: What the Vote Really Means

For three years, some of the most talked-about peptides in the world sat on a US government list with an uncomfortable name: bulk drug substances that raise significant safety concerns. Then, over two long days in July, a panel of advisers to the US Food and Drug Administration voted to recommend that six of them be allowed back into American pharmacies. It was the first time an FDA advisory committee had ever voted to widen access to these compounds, and it happened against the advice of the agency’s own scientists.

The vote was historic. It was also widely misunderstood. This article explains exactly what the committee voted on, peptide by peptide, why the debate was so close, what has to happen before anything changes in the US, and what it all means for researchers in the UK. Crown Peptides supplies these compounds as laboratory research materials only, and this piece reports on a US regulatory process rather than offering legal advice.

The Short Version

On 23 and 24 July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) met at the agency’s headquarters in Silver Spring, Maryland, to consider seven peptides for inclusion on the Section 503A Bulks List, the list of ingredients that traditional US compounding pharmacies may use to prepare prescriptions for individual patients. The committee voted in favour of six: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It voted against the seventh, emideltide, better known as DSIP.

The votes are recommendations. The FDA makes the final decision, and any change to the list has to go through formal rulemaking. Nothing about the vote changes the status of these compounds in the UK.

How Did These Peptides End Up Restricted in the First Place?

To understand why the July vote mattered, you need to know a little about how US pharmacy compounding works and how these peptides fell out of it.

What compounding pharmacies are for

In the US, compounding pharmacies prepare customised medicines for individual patients against a prescription: a liquid version of a tablet for a child who cannot swallow pills, for example, or a formulation without an ingredient a patient reacts to. Traditional compounding pharmacies are regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act and overseen largely by state boards of pharmacy.

A 503A pharmacy can generally only use a bulk ingredient if it meets one of three conditions: it is the subject of an official USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the 503A Bulks List. Most research peptides meet none of the first two conditions, so the Bulks List is the gateway.

The categories that decide what happens in the meantime

Building the Bulks List is slow, so the FDA uses interim categories for substances that have been nominated. Category 1 substances are under evaluation and, under the FDA’s enforcement discretion policy, can generally be compounded while that evaluation continues. Category 2 is for substances the agency believes raise significant safety risks, and compounding with them is not permitted.

In 2023, the FDA placed a group of popular peptides, including BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax and emideltide, into Category 2. For US clinics that had been prescribing compounded versions, that effectively shut the legal supply route.

The spring rethink

On 15 April 2026, the FDA announced that it would convene the PCAC in July to consider seven peptides for the Bulks List, and republished its interim list indicating that twelve peptides would come off Category 2 after a seven-day notice period. The removal did not move them into Category 1 or onto the Bulks List; it simply took away the “significant safety risk” label while the formal review happened. The FDA also identified five more peptides and peptide-derived substances, including LL-37, GHK-Cu for injection and Melanotan II, for later committee review.

The change came against a clear political backdrop. Health and Human Services Secretary Robert F. Kennedy Jr. has spoken publicly in favour of wider peptide access and of reversing the 2023 restrictions.

Two Days at White Oak: The Votes, Peptide by Peptide

For each peptide, the FDA reviewed specific proposed uses nominated for compounding, and the committee voted on whether the free base and acetate forms should be added to the Bulks List. Here is how each one went, with a little of the research background behind each compound.

BPC-157: 8 in favour, 6 against, 1 abstention

BPC-157 was reviewed for ulcerative colitis, and it was the most closely watched peptide of the meeting. It is a 15-amino-acid sequence derived from a protein in human gastric juice, studied for decades by Predrag Sikirić’s group at the University of Zagreb. Its research base is overwhelmingly preclinical but remarkably broad: a 2021 review in Frontiers in Pharmacology by Seiwerth, Sikirić and colleagues described healing research across skin, gut, tendon, ligament, muscle, bone, nerve and blood vessel models in animals (PMID: 34267654, PMC8275860). Its origins in the stomach and its famous stability in gastric acid help explain why a gastrointestinal indication was the one put forward.

KPV: 8 in favour, 6 against, 1 abstention

KPV was reviewed for wound healing and inflammatory conditions. It is a three-amino-acid fragment from the end of alpha-melanocyte-stimulating hormone, and its best-known research is a 2008 study in Gastroenterology by Dalmasso, Merlin and colleagues showing that nanomolar concentrations inhibited NF-kappaB and MAP kinase inflammatory signalling in human intestinal and immune cells, and reduced inflammation in two mouse models of colitis (PMID: 18061177, PMC2431115). The same study showed how such a tiny molecule gets into cells: through PepT1, a transporter that normally carries di- and tripeptides from digested food into the cells lining the gut, and which becomes more active in the colon during inflammation. That transport route is part of why KPV continues to attract so much gastrointestinal research interest.

TB-500: 8 in favour, 6 against, 1 abstention

TB-500 was reviewed for wound healing. It is based on thymosin beta-4, a protein that regulates actin, the scaffolding cells use to move. Research has indicated it may promote cell migration, blood vessel growth and tissue repair, including a widely cited 2004 Nature paper showing improved heart muscle survival and function after injury in mice (PMID: 15565145). Reports from the meeting noted that the same eight members voted yes, and the same six no, on each of the first three peptides.

MOTS-c: 7 in favour, 5 against, 2 abstentions

MOTS-c was reviewed for obesity and osteoporosis. It is a 16-amino-acid peptide encoded in the small genome inside mitochondria, first described in 2015. A 2021 study in Nature Communications by Reynolds, Lee and colleagues found it enhanced physical performance in young, middle-aged and old mice, and that exercise increases natural MOTS-c levels in human muscle and blood (PMID: 33473109, PMC7817689).

Epitalon: 7 in favour, 5 against, 1 abstention

Epitalon was reviewed for insomnia. It is a four-amino-acid peptide, Ala-Glu-Asp-Gly, developed at the Saint Petersburg Institute of Bioregulation and Gerontology from an extract of the pineal region, the part of the brain that produces melatonin. Its research centres on telomerase, melatonin rhythms and ageing markers, which is why a sleep-related use was nominated. Its best-known laboratory finding came in 2003, when Khavinson and colleagues reported in the Bulletin of Experimental Biology and Medicine that adding Epitalon to human fetal fibroblasts, cells that normally lack active telomerase, induced expression of the enzyme’s catalytic subunit, telomerase activity and telomere elongation (PMID: 12937682). A follow-up study the next year reported that treated cells went on to divide beyond their usual limit.

Semax: 8 in favour, 5 against

Semax was reviewed for cerebral ischaemia, migraine and trigeminal neuralgia. It is a seven-amino-acid peptide based on a fragment of ACTH, developed at the Institute of Molecular Genetics in Moscow and registered as a medicine in Russia, where its research focus has long been neuroprotection after stroke and brain-derived neurotrophic factor (BDNF). In a 2006 study in Brain Research, Dolotov and colleagues found that a single application of Semax in rats increased BDNF protein levels in the hippocampus, the brain’s key memory region, together with activation of its receptor, trkB, and a rise in learned avoidance responses (PMID: 16996037).

Emideltide (DSIP): 6 in favour, 7 against, 1 abstention

Emideltide, delta sleep-inducing peptide, was reviewed for insomnia, narcotic dependence and opioid withdrawal, and was the only one of the seven the committee did not recommend, by a single vote. DSIP is a nine-amino-acid peptide first isolated in the 1970s from the blood of rabbits in induced deep sleep, and it remains an intriguing research compound partly because no dedicated receptor for it has ever been identified.

The Question at the Heart of the Debate: “What Is It?”

The most striking thing about the meeting was not the split votes. It was the fundamental question the FDA’s own scientists kept raising.

The FDA staff position

In its briefing documents, the FDA proposed that none of the fourteen peptide forms under consideration, the free base and acetate versions of all seven compounds, be added to the Bulks List. Staff cited limited evidence on safety and effectiveness for the specific uses nominated, but also something more basic: the agency had encountered many substances marketed under the same name, such as “BPC-157”, that did not contain the same active molecule. Reports from the meeting quoted an FDA official telling the panel that the agency had never before faced the problem of not being sure what a substance actually is.

That is an unusual objection for a regulator to make, and an important one. Without a USP monograph or an approved drug to define a compound, there is no agreed specification of what “BPC-157” must contain, how pure it must be, or which impurities are acceptable.

Why the majority voted yes

Members who voted in favour frequently argued that patients were already obtaining these compounds from unregulated sources, and that bringing them into licensed pharmacies, under a prescription and a pharmacist’s oversight, would be safer than the status quo. Several framed it as a question of patient safety and access rather than as a verdict on efficacy.

Why the minority voted no

Members who voted against generally said there was not enough evidence of benefit for the specific uses nominated, and worried that inclusion on the list could be read by the public as an endorsement. It is worth noting, too, that the committee roster had been expanded before the meeting, and press reports observed that several newly appointed members worked at clinics offering peptides.

What Happens Next in the United States

This is where most coverage has been loose with the facts, so it is worth being precise.

The vote is advice, not a decision

PCAC is an advisory committee. The FDA is not legally required to follow its recommendations, although it is unusual for the agency to go against the committee. Until the FDA acts, the vote does not change what US compounding pharmacies may legally make.

Rulemaking takes time

For a substance to be added to the 503A Bulks List, the FDA must publish a proposed rule, take public comments and then publish a final rule. Regulatory lawyers have pointed to past precedent: a proposed rule covering ten other bulk substances was published in December 2016, and the final rule did not follow until February 2019, more than two years later. The final rule added six of those substances and excluded four, so the committee’s recommendations and the agency’s final decisions do not always match.

What rulemaking actually involves

Because the phrase “rulemaking” hides a lot of process, here is what each stage means in practice.

The proposed rule

The FDA first drafts a proposed rule setting out which substances it intends to add to, or exclude from, the Bulks List, together with its reasoning. That document is published in the Federal Register, the official journal of the US government, and it does not have to mirror the committee’s votes.

Public comment

Once the proposed rule is published, anyone can submit comments: pharmacies, clinicians, manufacturers, patient groups and researchers. The FDA must consider the substantive comments it receives. Given the scale of public interest these peptides attracted in the run-up to the July meeting, that stage is likely to be substantial.

The final rule

After reviewing comments, the FDA publishes a final rule that formally updates the list, with an effective date. Only at that point would any of these peptides become eligible for 503A compounding. Until then, they remain outside the list, even though they are no longer labelled as Category 2 safety risks.

Five more peptides are in the queue

The July meeting was not the end of the process. The FDA has said it expects to bring five further substances to the committee before February 2027: LL-37 (cathelicidin), Dihexa acetate, injectable GHK-Cu, pegylated mechano growth factor and Melanotan II. For anyone following peptide research, that next meeting will be just as interesting.

Does Any of This Change Things in the UK?

No. The FDA regulates medicines in the United States. The 503A Bulks List governs what US pharmacies may compound. None of it applies in the UK, where medicines are regulated by the Medicines and Healthcare products Regulatory Agency under the Human Medicines Regulations 2012.

In the UK, BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax and DSIP are not controlled drugs and are available as research materials, as they were before the vote. Our guides are peptides legal in the UK and is BPC-157 legal in the UK explain the UK framework in detail.

What the vote does show is how quickly international interest in these compounds is growing, and how seriously regulators are now engaging with them. That is good news for the research field as a whole: more scrutiny tends to mean more data, clearer standards and better science.

Why UK researchers should still follow the story

Even though the US process has no legal effect here, it is worth watching closely for three reasons.

First, the FDA’s briefing documents and the committee discussion are a rare, public, expert review of the evidence for each compound, and they will be followed by further documents as rulemaking progresses. For anyone designing research, they are a useful map of where the evidence is strongest and where the gaps are.

Second, if US pharmacies do begin compounding these peptides, pressure for agreed quality specifications will grow. That could eventually mean official monographs defining identity, purity and acceptable impurities for compounds such as BPC-157, which would raise the bar for everyone supplying them, including research suppliers.

Third, regulatory attention tends to draw research funding and publication activity behind it. The more seriously regulators engage with these compounds, the more likely it is that new, better-designed studies will appear, and that is exactly what the field needs.

The Identity Problem Is a Quality Problem

For researchers, the most useful takeaway from the whole meeting is the FDA’s “what is it?” concern, because it is precisely the problem that analytical testing exists to solve.

If products sold under one name contain different molecules, then any research using them is built on sand. The fix is not complicated, but it is not optional: every batch should be tested to confirm both what the molecule is and how pure it is. Mass spectrometry weighs the molecule and confirms its identity against the expected mass. High-performance liquid chromatography separates it from related impurities and measures purity. Together they answer the FDA’s question for any individual vial.

The need is real. Anti-doping scientists in Cologne have documented black market growth hormone peptides carrying a single extra amino acid, molecules that looked right until mass spectrometry showed otherwise. Our guide to peptide testing in the UK tells that story in full.

The Crown Peptides standard

Every batch Crown Peptides supplies, including all six of the peptides recommended in July and DSIP, comes with a batch-specific certificate of analysis showing HPLC purity and mass spectrometry identity confirmation, with lot numbers matching the vial labels. Published certificates are on our Lab Reports page, and our guide to reading a certificate of analysis explains every figure.

The Technical Breakdown: Decoding the Regulatory Language

US compounding regulation comes with its own vocabulary. This section decodes the key terms for anyone who wants to follow the story as it develops.

503A versus 503B

Section 503A covers traditional compounding pharmacies that prepare medicines for identified individual patients against a prescription. Section 503B covers outsourcing facilities, which can compound in larger batches, with or without individual prescriptions, under stricter manufacturing standards and closer FDA oversight. The July vote concerned only the 503A Bulks List.

Compounding versus drug approval

Drug approval is the process by which the FDA evaluates a specific finished product, at a specific strength, for a specific use, based on clinical trials and a defined manufacturing process, and authorises it for sale. Inclusion on the Bulks List is different: it makes a bulk ingredient eligible for use by pharmacies preparing individual prescriptions. It does not approve any product or confirm any use.

Free base and acetate

The committee voted on the free base and acetate forms of each peptide separately. The free base is the peptide on its own; the acetate is the peptide paired with acetate counter-ions, a salt form that is common for synthetic peptides and often preferred for stability and handling. Both forms were considered because both are used in manufacturing.

Nominated uses

When a substance is nominated for the Bulks List, the nomination names specific uses, and the FDA evaluates the evidence for those uses. That is why the meeting discussed BPC-157 in the context of ulcerative colitis, for example, rather than every area in which it has been researched.

Monographs

A USP monograph is an official standard published by the United States Pharmacopeia that defines a substance’s identity, strength, quality and purity, along with the tests used to check them. None of the seven peptides currently has one, which is exactly why the FDA’s “what is it?” question carried so much weight.

Related Compounds in This Story

Every peptide reviewed in July is part of the Crown Peptides research range, along with several of those expected at the next meeting.

The six recommended peptides

BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax are all available as research compounds. BPC-157 and TB-500 are also combined in the Wolverine Stack (BPC-157 + TB-500 Blend), while KLOW brings BPC-157, TB-500 and KPV together with GHK-Cu. Semax is paired with its sister peptide in the Semax 5mg + Selank 5mg (Blend).

DSIP

DSIP remains available for sleep research, with its full story in our DSIP guide.

The next group under review

LL-37, GHK-Cu and Melanotan-2 are among the substances the FDA expects to bring to the committee before February 2027.

For deeper background on individual compounds, see our guides to BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax.

Questions People Are Asking About the Vote

Did the FDA approve BPC-157?

No. An FDA advisory committee recommended that BPC-157 be added to the list of bulk substances US compounding pharmacies may use. The FDA itself has not yet acted on that recommendation, and inclusion on the list would not be the same as approval of a drug.

Which peptides did the panel recommend?

BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It voted against emideltide (DSIP).

When will US pharmacies be able to compound them?

Not until the FDA completes rulemaking to add them to the 503A Bulks List. Past precedent suggests that process can take a year or more, and the final outcome may differ from the committee’s recommendations.

Why did FDA scientists oppose the recommendations?

They cited limited evidence for the specific nominated uses and a more fundamental problem: products sold under the same peptide name had been found to contain different molecules, with no official monograph defining what each substance should be.

Does the vote affect UK buyers?

No. It concerns US compounding pharmacies only. The UK status of these compounds as research materials is unchanged.

A Turning Point Worth Watching

Three years ago, these peptides were labelled as significant safety risks by the US regulator. This summer, a formal advisory committee heard the evidence, debated it openly and recommended that six of them come back into licensed pharmacy practice. Whatever the FDA ultimately decides, the conversation has shifted from whether these compounds deserve serious attention to how they should be defined, tested and studied.

That last question is where researchers come in. The FDA’s central worry, not knowing exactly what is in a product, is solved one batch at a time with proper analysis. If you are researching any of the compounds in this story, start with material whose identity and purity you can verify. Explore the Crown Peptides research peptides range, every batch HPLC and mass spectrometry verified, with published certificates and UK dispatch.